Hankimball, my thoughts were just that if TDX sells all of its...

Hankimball, my thoughts were just that if TDX sells all of its biotech activities, then the biomarker payment would go to the mob that the biotech activities are sold to. If TDX has those activities lay dormant instead of a sale, then the company probably wouldn't be eligible for the payment if the activities do not ensue.

I am only very new at looking at TDX, so take my thoughts with a grain of salt, because I just don't know enough. The above, though, just seems logical. Maybe the company will just continue in biotech. They have wound down a lot now, though, so it's hard to know how much they will be progressing in the biotech stakes. This is when holders might want staff and management back, but if the company cannot afford them, then it does seem more like a shell. It depends on whether "unfinished business" becomes ongoing business, or an exit.